Registered title, quoted from ClinicalTrials.gov
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Sixth Affiliated Hospital of Sun Yat-sen University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06871527, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically determined gastric or gastroesophageal junction adenocarcinoma;
Inclusion criterion 3
Had a major surgical procedure (thoracotomy, or laparotomy , etc.) within 4 weeks prior to the first dose of study therapy;
Exclusion criterion 13
Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
Inclusion criterion 2
At least one measurable lesion according to RECIST version 1.1;
Inclusion criterion 6
Pregnant or lactating women, or patients of childbearing age who refused contraception during the study period;
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06871527, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 18-75 years old (including 18 and 75 years old);
- Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
- Pathologically determined gastric or gastroesophageal junction adenocarcinoma;
- Advanced patients with radiographic confirmation of inoperable complete resection;
- No previous anti-tumor treatment for metastatic diseases;
- At least one measurable lesion according to RECIST version 1.1;
- Ability to take medications orally;
- No active bleeding;
- Adequate organ functions:
Absolute neutrophil count ≥2×109/L; Platelet ≥100×109/L; Hemoglobin ≥90g/L; WBC≥4×109/L Total bilirubin ≤ 1.5XULN; ALT and AST ≤2.5XULN ; Serum creatinine (Cr) ≤1.5XULN;
- Have fully understood the study and voluntarily signed the informed consent;
Exclusion Criteria:
- Patients who had received any drug in the study protocol in the last year;
- Deficient mismatch repair (dMMR) or MSI-H detected by genetic test;
- HER2 positive(HER-2 3+, or HER-2 2+ and FISH+);
- Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg;
- Patients with acute coronary syndromes (including myocardial infarction and unstable angina) received coronary angioplasty or stenting within 6 months before enrollment;
- Patients with massive pleural or peritoneal effusion requiring drainage;
- Patients with severe ECG abnormalities or heart diseases (such as cardiac insufficiency, myocardial infarction, angina pectoris) that affect clinical treatment;
- Severe lung diseases (such as interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.);
- Mental disorders or central nervous system diseases or brain metastases affecting clinical treatment;
- Patients with autoimmune diseases;
- Patients with grade 3 or higher bleeding within 4 weeks;
- Patients with a history of allergy to any drug, similar drug or vehicle in this study;
- Had a major surgical procedure (thoracotomy, or laparotomy , etc.) within 4 weeks prior to the first dose of study therapy;
- Patients with nonhealed wounds, ulcers, or fractures;
- Patients who required systemic corticosteroids (excluding temporary testing, prophylactic administration for anaphylaxis), or immunosuppressive agents or had received such agents within 14 days before enrollment;
- Pregnant or lactating women, or patients of childbearing age who refused contraception during the study period;
- Investigators believe that the patient has any other conditions that are not suitable for participating in the study.
Quoted from ClinicalTrials.gov, NCT06871527, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06871527, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.